As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola Life Science Investing
Radoff-JEC Group Announces That Glass Lewis Has Joined ISS in Supporting its Case for Change at Seer, Inc. Life Science Investing
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia Life Science Investing
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune Life Science Investing
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 Biotech Investing
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Life Science Investing
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom Life Science Investing
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock Life Science Investing
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Life Science Investing
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference Life Science Investing
